Loading…
How Clavulanic Acid Inhibits Serine β‐Lactamases
Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS)...
Saved in:
Published in: | Chembiochem : a European journal of chemical biology 2024-11, Vol.25 (22), p.e202400280-n/a |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3 |
container_end_page | n/a |
container_issue | 22 |
container_start_page | e202400280 |
container_title | Chembiochem : a European journal of chemical biology |
container_volume | 25 |
creator | Lang, Pauline A. Munnik, Mariska Oluwole, Abraham O. Claridge, Timothy D. W. Robinson, Carol V. Brem, Jürgen Schofield, Christopher J. |
description | Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest.
Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition. |
doi_str_mv | 10.1002/cbic.202400280 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084773193</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3084773193</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</originalsourceid><addsrcrecordid>eNqFkEFOwzAQRS0EolDYskSR2LBJGXucOFmWCGilSiyAteU4jnCVNCVuqLrjCJyFg3AIToKrliKxYTV_pDd_vj4hZxQGFIBd6dzqAQPG_ZLAHjmiHNNQxIj7W80ZEz1y7NwUANIY6SHpYQoRE3F0RHDULIOsUq9dpWZWB0Nti2A8e7a5XbjgwbR2ZoLPj6-394nSC1UrZ9wJOShV5czpdvbJ0-3NYzYKJ_d342w4CTWLEggLwfwblTMoFM_BC1SojTI8NSASnwB4IbQukxiZNpgLTFkuuFCGRpEosU8uN77ztnnpjFvI2jptKp_UNJ2TCAkXAmmKHr34g06brp35dBIpSxORCFxTgw2l28a51pRy3tpatStJQa7rlOs65a5Of3C-te3y2hQ7_Kc_D6QbYGkrs_rHTmbX4-zX_BuwJoAu</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3129878733</pqid></control><display><type>article</type><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><source>Wiley</source><creator>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</creator><creatorcontrib>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</creatorcontrib><description>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest.
Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</description><identifier>ISSN: 1439-4227</identifier><identifier>ISSN: 1439-7633</identifier><identifier>EISSN: 1439-7633</identifier><identifier>DOI: 10.1002/cbic.202400280</identifier><identifier>PMID: 39052765</identifier><language>eng</language><publisher>Germany: Wiley Subscription Services, Inc</publisher><subject>Acids ; Antimicrobial resistance ; beta-Lactamase Inhibitors - chemical synthesis ; beta-Lactamase Inhibitors - chemistry ; beta-Lactamase Inhibitors - pharmacology ; beta-Lactamases - chemistry ; beta-Lactamases - metabolism ; Clavulanic acid ; Clavulanic Acid - chemistry ; Clavulanic Acid - pharmacology ; Complex formation ; E coli ; Escherichia coli - drug effects ; Escherichia coli - enzymology ; Fragmentation ; In vivo methods and tests ; Mass spectrometry ; Mass spectroscopy ; Mechanism-based inhibition ; Oxazolidine ; Penam sulfone ; Ring opening ; Scaffolds ; Serine ; Serine - chemistry ; Serine - metabolism ; Serine β-lactamase inhibitor ; Sulfones ; β Lactamase</subject><ispartof>Chembiochem : a European journal of chemical biology, 2024-11, Vol.25 (22), p.e202400280-n/a</ispartof><rights>2024 The Authors. ChemBioChem published by Wiley-VCH GmbH</rights><rights>2024 The Authors. ChemBioChem published by Wiley-VCH GmbH.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</cites><orcidid>0000-0002-0290-6565</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39052765$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lang, Pauline A.</creatorcontrib><creatorcontrib>Munnik, Mariska</creatorcontrib><creatorcontrib>Oluwole, Abraham O.</creatorcontrib><creatorcontrib>Claridge, Timothy D. W.</creatorcontrib><creatorcontrib>Robinson, Carol V.</creatorcontrib><creatorcontrib>Brem, Jürgen</creatorcontrib><creatorcontrib>Schofield, Christopher J.</creatorcontrib><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><title>Chembiochem : a European journal of chemical biology</title><addtitle>Chembiochem</addtitle><description>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest.
Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</description><subject>Acids</subject><subject>Antimicrobial resistance</subject><subject>beta-Lactamase Inhibitors - chemical synthesis</subject><subject>beta-Lactamase Inhibitors - chemistry</subject><subject>beta-Lactamase Inhibitors - pharmacology</subject><subject>beta-Lactamases - chemistry</subject><subject>beta-Lactamases - metabolism</subject><subject>Clavulanic acid</subject><subject>Clavulanic Acid - chemistry</subject><subject>Clavulanic Acid - pharmacology</subject><subject>Complex formation</subject><subject>E coli</subject><subject>Escherichia coli - drug effects</subject><subject>Escherichia coli - enzymology</subject><subject>Fragmentation</subject><subject>In vivo methods and tests</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Mechanism-based inhibition</subject><subject>Oxazolidine</subject><subject>Penam sulfone</subject><subject>Ring opening</subject><subject>Scaffolds</subject><subject>Serine</subject><subject>Serine - chemistry</subject><subject>Serine - metabolism</subject><subject>Serine β-lactamase inhibitor</subject><subject>Sulfones</subject><subject>β Lactamase</subject><issn>1439-4227</issn><issn>1439-7633</issn><issn>1439-7633</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNqFkEFOwzAQRS0EolDYskSR2LBJGXucOFmWCGilSiyAteU4jnCVNCVuqLrjCJyFg3AIToKrliKxYTV_pDd_vj4hZxQGFIBd6dzqAQPG_ZLAHjmiHNNQxIj7W80ZEz1y7NwUANIY6SHpYQoRE3F0RHDULIOsUq9dpWZWB0Nti2A8e7a5XbjgwbR2ZoLPj6-394nSC1UrZ9wJOShV5czpdvbJ0-3NYzYKJ_d342w4CTWLEggLwfwblTMoFM_BC1SojTI8NSASnwB4IbQukxiZNpgLTFkuuFCGRpEosU8uN77ztnnpjFvI2jptKp_UNJ2TCAkXAmmKHr34g06brp35dBIpSxORCFxTgw2l28a51pRy3tpatStJQa7rlOs65a5Of3C-te3y2hQ7_Kc_D6QbYGkrs_rHTmbX4-zX_BuwJoAu</recordid><startdate>20241118</startdate><enddate>20241118</enddate><creator>Lang, Pauline A.</creator><creator>Munnik, Mariska</creator><creator>Oluwole, Abraham O.</creator><creator>Claridge, Timothy D. W.</creator><creator>Robinson, Carol V.</creator><creator>Brem, Jürgen</creator><creator>Schofield, Christopher J.</creator><general>Wiley Subscription Services, Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-0290-6565</orcidid></search><sort><creationdate>20241118</creationdate><title>How Clavulanic Acid Inhibits Serine β‐Lactamases</title><author>Lang, Pauline A. ; Munnik, Mariska ; Oluwole, Abraham O. ; Claridge, Timothy D. W. ; Robinson, Carol V. ; Brem, Jürgen ; Schofield, Christopher J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acids</topic><topic>Antimicrobial resistance</topic><topic>beta-Lactamase Inhibitors - chemical synthesis</topic><topic>beta-Lactamase Inhibitors - chemistry</topic><topic>beta-Lactamase Inhibitors - pharmacology</topic><topic>beta-Lactamases - chemistry</topic><topic>beta-Lactamases - metabolism</topic><topic>Clavulanic acid</topic><topic>Clavulanic Acid - chemistry</topic><topic>Clavulanic Acid - pharmacology</topic><topic>Complex formation</topic><topic>E coli</topic><topic>Escherichia coli - drug effects</topic><topic>Escherichia coli - enzymology</topic><topic>Fragmentation</topic><topic>In vivo methods and tests</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Mechanism-based inhibition</topic><topic>Oxazolidine</topic><topic>Penam sulfone</topic><topic>Ring opening</topic><topic>Scaffolds</topic><topic>Serine</topic><topic>Serine - chemistry</topic><topic>Serine - metabolism</topic><topic>Serine β-lactamase inhibitor</topic><topic>Sulfones</topic><topic>β Lactamase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lang, Pauline A.</creatorcontrib><creatorcontrib>Munnik, Mariska</creatorcontrib><creatorcontrib>Oluwole, Abraham O.</creatorcontrib><creatorcontrib>Claridge, Timothy D. W.</creatorcontrib><creatorcontrib>Robinson, Carol V.</creatorcontrib><creatorcontrib>Brem, Jürgen</creatorcontrib><creatorcontrib>Schofield, Christopher J.</creatorcontrib><collection>Wiley Open Access</collection><collection>Wiley-Blackwell Backfiles (Open access)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chembiochem : a European journal of chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lang, Pauline A.</au><au>Munnik, Mariska</au><au>Oluwole, Abraham O.</au><au>Claridge, Timothy D. W.</au><au>Robinson, Carol V.</au><au>Brem, Jürgen</au><au>Schofield, Christopher J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>How Clavulanic Acid Inhibits Serine β‐Lactamases</atitle><jtitle>Chembiochem : a European journal of chemical biology</jtitle><addtitle>Chembiochem</addtitle><date>2024-11-18</date><risdate>2024</risdate><volume>25</volume><issue>22</issue><spage>e202400280</spage><epage>n/a</epage><pages>e202400280-n/a</pages><issn>1439-4227</issn><issn>1439-7633</issn><eissn>1439-7633</eissn><abstract>Clavulanic acid is a medicinally important inhibitor of serine β‐lactamases (SBLs). We report studies on the mechanisms by which clavulanic acid inhibits representative Ambler class A (TEM‐116), C (Escherichia coli AmpC), and D (OXA‐10) SBLs using denaturing and non‐denaturing mass spectrometry (MS). Similarly to observations with penam sulfones, most of the results support a mechanism involving acyl enzyme complex formation, followed by oxazolidine ring opening without efficient subsequent scaffold fragmentation (at pH 7.5). This observation contrasts with previous MS studies, which identified clavulanic acid scaffold fragmented species as the predominant SBL bound products. In all the SBLs studied here, fragmentation was promoted by acidic conditions, which are commonly used in LC–MS analyses. Slow fragmentation was, however, observed under neutral conditions with TEM‐116 on prolonged reaction with clavulanic acid. Although our results imply clavulanic acid scaffold fragmentation is likely not crucial for SBL inhibition in vivo, development of inhibitors that fragment to give stable covalent complexes is of interest.
Inhibition of serine β‐lactamases by clavulanic acid occurs via a bifurcating mechanism. The formation of an acyl‐enzyme complex may be followed by hydrolysis, or oxazolidine ring opening and subsequent decarboxylation to give more stable species. Further fragmentation is slow and is less likely to be biologically relevant in inhibition.</abstract><cop>Germany</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39052765</pmid><doi>10.1002/cbic.202400280</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0290-6565</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1439-4227 |
ispartof | Chembiochem : a European journal of chemical biology, 2024-11, Vol.25 (22), p.e202400280-n/a |
issn | 1439-4227 1439-7633 1439-7633 |
language | eng |
recordid | cdi_proquest_miscellaneous_3084773193 |
source | Wiley |
subjects | Acids Antimicrobial resistance beta-Lactamase Inhibitors - chemical synthesis beta-Lactamase Inhibitors - chemistry beta-Lactamase Inhibitors - pharmacology beta-Lactamases - chemistry beta-Lactamases - metabolism Clavulanic acid Clavulanic Acid - chemistry Clavulanic Acid - pharmacology Complex formation E coli Escherichia coli - drug effects Escherichia coli - enzymology Fragmentation In vivo methods and tests Mass spectrometry Mass spectroscopy Mechanism-based inhibition Oxazolidine Penam sulfone Ring opening Scaffolds Serine Serine - chemistry Serine - metabolism Serine β-lactamase inhibitor Sulfones β Lactamase |
title | How Clavulanic Acid Inhibits Serine β‐Lactamases |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T09%3A27%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=How%20Clavulanic%20Acid%20Inhibits%20Serine%20%CE%B2%E2%80%90Lactamases&rft.jtitle=Chembiochem%20:%20a%20European%20journal%20of%20chemical%20biology&rft.au=Lang,%20Pauline%20A.&rft.date=2024-11-18&rft.volume=25&rft.issue=22&rft.spage=e202400280&rft.epage=n/a&rft.pages=e202400280-n/a&rft.issn=1439-4227&rft.eissn=1439-7633&rft_id=info:doi/10.1002/cbic.202400280&rft_dat=%3Cproquest_cross%3E3084773193%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c2580-d72905ab20da4b0ab23a3ceae49e07805204d7ccf8632ce3b7392b747ae1557f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3129878733&rft_id=info:pmid/39052765&rfr_iscdi=true |